OVID Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ovid Therapeutics Inc (OVID) is not a strong buy for a beginner investor with a long-term focus at this time. While there are positive developments in its pipeline and analyst ratings are favorable, the lack of immediate trading signals, weak financial performance, and hedge fund selling trends suggest a cautious approach. The stock may be worth monitoring for future developments.
The technical indicators are mixed. The MACD is negative and expanding downward, suggesting bearish momentum. RSI is neutral at 44.885, indicating no clear overbought or oversold condition. However, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the pre-market price shows a slight upward trend (+1.12%). Key support and resistance levels are at S1: 2.635 and R1: 2.952.
Analyst ratings are consistently positive, with raised price targets from multiple firms (e.g., H.C. Wainwright to $4, Wedbush to $7, Roth Capital to $5). The company's OV329 and KCC2 portfolio show promise with upcoming clinical milestones and potential therapeutic applications. The pre-market price is up 1.12%, reflecting some positive sentiment.
Hedge funds are significantly selling the stock, with a 668.25% increase in selling activity last quarter. Financial performance in Q4 2025 shows a sharp drop in net income (-204.43% YoY) and EPS (-192.31% YoY), despite revenue growth. No recent news or congress trading data to provide additional support.
In Q4 2025, revenue increased by 844.74% YoY to $718,000, but net income dropped significantly by -204.43% YoY to -$9.66M, and EPS fell by -192.31% YoY to $0.12. Gross margin remained strong at 100%, but overall financials indicate poor profitability.
Analysts are optimistic about OVID, with multiple firms raising price targets and maintaining Buy or Outperform ratings. H.C. Wainwright, Wedbush, and Roth Capital highlight the potential of OV329 and KCC2 portfolios, with increased confidence in clinical milestones and therapeutic applications.
